TY - JOUR
T1 - Treatment of retinal diseases with VEGF antagonists
AU - Schlingemann, R. O.
AU - Witmer, A. N.
PY - 2009
Y1 - 2009
N2 - Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the most prevalent causes of blindness in the Western world. The pathogenesis of neovascularization and vascular leakage, both hallmarks of these diseases, appears to have one common denominator: vascular endothelial growth factor (VEGF). Since the recent introduction of anti-VEGF therapy, intravitreal injections with these agents have become standard care in neovascular AMD, and have been found to be a valuable additional treatment strategy in several other vascular retinal diseases. This review provides an overview of the history of anti-VEGF treatment in the eye, its rationale, its efficacy, and its potential drawbacks
AB - Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the most prevalent causes of blindness in the Western world. The pathogenesis of neovascularization and vascular leakage, both hallmarks of these diseases, appears to have one common denominator: vascular endothelial growth factor (VEGF). Since the recent introduction of anti-VEGF therapy, intravitreal injections with these agents have become standard care in neovascular AMD, and have been found to be a valuable additional treatment strategy in several other vascular retinal diseases. This review provides an overview of the history of anti-VEGF treatment in the eye, its rationale, its efficacy, and its potential drawbacks
U2 - https://doi.org/10.1016/S0079-6123(09)17517-9
DO - https://doi.org/10.1016/S0079-6123(09)17517-9
M3 - Review article
C2 - 19660661
SN - 0079-6123
VL - 175
SP - 253
EP - 267
JO - Progress in brain research
JF - Progress in brain research
ER -